Quantum Biopharma Ltd. (CVE:QNT – Free Report) – Research analysts at Singular Research issued their Q1 2026 earnings estimates for shares of Quantum Biopharma in a note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan anticipates that the company will earn ($0.10) per share for the quarter. Singular Research currently has a “Moderate Buy” rating on the stock. Singular Research also issued estimates for Quantum Biopharma’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.48) EPS and Q4 2026 earnings at ($0.73) EPS.
Quantum Biopharma Stock Performance
Insider Activity
In other news, Senior Officer Nathan Patrick Coyle sold 3,000 shares of Quantum Biopharma stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of C$20.16, for a total value of C$60,480.00.
See Also
- Five stocks we like better than Quantum Biopharma
- Earnings Per Share Calculator: How to Calculate EPS
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- D-Wave Goes International With South Korea Partnership
- How to Calculate Stock Profit
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.